business
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
Archived — last updated
T-MAXIMUM Pharmaceutical has received United States Food and Drug Administration clearance to begin a Phase 2 clinical study of MT027, its B7-H3-targeted allogeneic CAR-T therapy, for patients with brain metastases from lung cancer and…
Latest updates
No updates on this story yet.
AI-assisted summary of the reporting above. Quotes are kept to one sentence. Copyright concern? See our DMCA takedown page.
Related stories
France plans €4bn education spending amid debt concerns and nationwide protests
France plans €4bn for schools and €1bn for universities despite 120% debt and nationwide protests.
India raises fiscal year growth forecast to 7.3% amid Middle East instability
India's Ministry of Finance expects India's economy to grow at a pace of 7.3% in the current fiscal year based on its latest assessment of
EU Industrial Accelerator Act risks hurting auto suppliers in Turkey and Morocco
EU's new Industrial Accelerator Act risks hurting auto suppliers in Turkey and Morocco by restricting subsidies to European-made vehicles.